Pyxis Oncology, Inc. Capital Expenditures
Pyxis Oncology, Inc. (PYXS) reported Capital Expenditures of $9.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-03-23
- Pyxis Oncology, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $0.00.
- Pyxis Oncology, Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-12-31 was $0.00.
- Pyxis Oncology, Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Pyxis Oncology, Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Pyxis Oncology, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $9.00K, a 96.20% decline from fiscal 2024.
- Pyxis Oncology, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $237.00K, a 96.48% decline from fiscal 2023.
- Pyxis Oncology, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $6.73M, a 5.11% increase from fiscal 2022.
- Pyxis Oncology, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $6.40M, a 1085.00% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $9.00K 10-K · filed 2026-03-23 | ||
| 2025-09-30 | $9.00K 10-Q · filed 2025-11-03 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 derived: sum of 3 quarters · filed 2026-03-23 | $237.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-03 | $237.00K 10-Q · filed 2025-11-03 | $237.00K derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $237.00K 10-Q · filed 2025-08-14 | $237.00K derived: sum of 3 quarters · filed 2025-08-14 | $298.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $237.00K 10-Q · filed 2025-05-15 | $237.00K derived: sum of 2 quarters · filed 2025-05-15 | $298.00K derived: sum of 3 quarters · filed 2025-05-15 | $2.56M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $61.00K derived: sum of 2 quarters · filed 2025-03-18 | $2.32M derived: sum of 3 quarters · filed 2025-03-18 | $6.73M 10-K · filed 2025-03-18 |
| 2023-09-30 | $61.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.32M derived: sum of 2 quarters · filed 2024-11-12 | $6.73M 10-Q · filed 2024-11-12 | $8.58M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $2.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $6.67M 10-Q · filed 2024-08-14 | $8.52M derived: sum of 3 quarters · filed 2024-08-14 | $12.79M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $4.41M 10-Q · filed 2024-05-14 | $6.26M derived: sum of 2 quarters · filed 2024-05-14 | $10.53M derived: sum of 3 quarters · filed 2024-05-14 | $10.66M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $6.12M derived: sum of 2 quarters · filed 2024-03-21 | $6.25M derived: sum of 3 quarters · filed 2024-03-21 | $6.40M 10-K · filed 2024-03-21 |
| 2022-09-30 | $4.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $4.39M derived: sum of 2 quarters · filed 2023-11-07 | $4.54M 10-Q · filed 2023-11-07 | $4.54M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $129.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $275.00K 10-Q · filed 2023-08-11 | $275.00K derived: sum of 3 quarters · filed 2023-08-11 | $275.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $146.00K 10-Q · filed 2023-05-11 | $146.00K derived: sum of 2 quarters · filed 2023-05-11 | $146.00K derived: sum of 3 quarters · filed 2023-05-11 | $517.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $0.00 derived: sum of 2 quarters · filed 2023-03-22 | $371.00K derived: sum of 3 quarters · filed 2023-03-22 | $540.00K 10-K · filed 2023-03-22 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $371.00K derived: sum of 2 quarters · filed 2022-11-01 | $540.00K 10-Q · filed 2022-11-01 | $540.00K derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $371.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $540.00K 10-Q · filed 2022-08-15 | $540.00K derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | $169.00K 10-Q · filed 2022-05-13 | $169.00K derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $1.48M 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $1.48M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |